[
  {
    "ts": null,
    "headline": "JPM26: BioNTech gears up for multiproduct oncology status by 2030",
    "summary": "Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.",
    "url": "https://finnhub.io/api/news?id=e117a0e4d31664e25dfdecb214d278aabe399e446b1f9a8c10e2a5b3a3155eb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395569,
      "headline": "JPM26: BioNTech gears up for multiproduct oncology status by 2030",
      "id": 138111268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.",
      "url": "https://finnhub.io/api/news?id=e117a0e4d31664e25dfdecb214d278aabe399e446b1f9a8c10e2a5b3a3155eb9"
    }
  },
  {
    "ts": null,
    "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
    "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
    "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394700,
      "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
      "id": 138111148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
      "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca"
    }
  },
  {
    "ts": null,
    "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
    "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
    "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394359,
      "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
      "id": 138113004,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222153/image_2194222153.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
      "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc"
    }
  },
  {
    "ts": null,
    "headline": "Here's 7 Ideal \"Safer\" January Dividend Dogs In The S&P500",
    "summary": "Seven S&P 500 high-yield 'safer' dividend stocksâlike Ford, AT&T, and VICIâoffer strong payouts supported by free cash flow and attractive valuations. Read the full list here.",
    "url": "https://finnhub.io/api/news?id=8e70c97c632e32c4a90bce513d9cf130368557c18a5247bd432e7e49ee8e236f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394236,
      "headline": "Here's 7 Ideal \"Safer\" January Dividend Dogs In The S&P500",
      "id": 138112924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431765767/image_1431765767.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Seven S&P 500 high-yield 'safer' dividend stocksâlike Ford, AT&T, and VICIâoffer strong payouts supported by free cash flow and attractive valuations. Read the full list here.",
      "url": "https://finnhub.io/api/news?id=8e70c97c632e32c4a90bce513d9cf130368557c18a5247bd432e7e49ee8e236f"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
    "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392531,
      "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
      "id": 138112555,
      "image": "https://image.cnbcfm.com/api/v1/image/108222573-17624550972025-11-06t184628z_1673660215_rc25rhas1dn5_rtrmadp_0_usa-trump.jpeg?v=1762455130&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan",
    "summary": "BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-sta",
    "url": "https://finnhub.io/api/news?id=f7cfa3e861d60dc629fd48ce5dfc5897a644d224cf15f87a20c65d5fed756410",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768381456,
      "headline": "BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan",
      "id": 138109907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-sta",
      "url": "https://finnhub.io/api/news?id=f7cfa3e861d60dc629fd48ce5dfc5897a644d224cf15f87a20c65d5fed756410"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
    "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768379400,
      "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 138109921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
      "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281"
    }
  },
  {
    "ts": null,
    "headline": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
    "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
    "url": "https://finnhub.io/api/news?id=b6d9a7bd9560994cbf376ac02dc752c173bda0fc5d71a30f3ff65a30dd83c62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768356284,
      "headline": "Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025",
      "id": 138092350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol",
      "url": "https://finnhub.io/api/news?id=b6d9a7bd9560994cbf376ac02dc752c173bda0fc5d71a30f3ff65a30dd83c62f"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
    "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
    "url": "https://finnhub.io/api/news?id=2cad85838480923bf8fd7109d37f7179b6424fd2effefbf57dbf87efb02da617",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768350319,
      "headline": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions",
      "id": 138092351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.",
      "url": "https://finnhub.io/api/news?id=2cad85838480923bf8fd7109d37f7179b6424fd2effefbf57dbf87efb02da617"
    }
  }
]